dc.creator | Muñoz Hernández, Rocío | es |
dc.creator | Gato, Sheila | es |
dc.creator | Gil-Gomez, Antonio | es |
dc.creator | Aller, Rocio | es |
dc.creator | Rojas, Angela | es |
dc.creator | Moran, Laura | es |
dc.creator | Ampuero Herrojo, Javier | es |
dc.creator | Romero Gómez, Manuel | es |
dc.date.accessioned | 2024-06-25T09:57:51Z | |
dc.date.available | 2024-06-25T09:57:51Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Muñoz Hernández, R., Gato, S., Gil-Gomez, A., Aller, R., Rojas, A., Moran, L.,...,Romero Gómez, M. (2023). Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD. Liver International, 43 (9), 1909-1919. https://doi.org/10.1111/liv.15604. | |
dc.identifier.issn | 1478-3223 | es |
dc.identifier.issn | 1478-3231 | es |
dc.identifier.uri | https://hdl.handle.net/11441/160846 | |
dc.description.abstract | Background and Aims
Extracellular vesicles (EVs) have emerged as a potential source of circulating biomarkers in liver disease. We evaluated circulating AV+ EpCAM+ CD133+ EVs as a potential biomarker of the transition from simple steatosis to steatohepatitis.
Methods
EpCAM and CD133 liver proteins and EpCAM+ CD133+ EVs levels were analysed in 31 C57BL/6J mice fed with a chow or high fat, high cholesterol and carbohydrates diet (HFHCC) for 52 weeks. The hepatic origin of MVs was addressed using AlbCrexmT/mG mice fed a Western (WD) or Dual diet for 23 weeks. Besides, we assessed plasma MVs in 130 biopsy-proven NAFLD patients.
Results
Hepatic expression of EpCAM and CD133 and EpCAM+ CD133+ EVs increased during disease progression in HFHCC mice. GFP+ MVs were higher in AlbCrexmT/mG mice fed a WD (5.2% vs 12.1%) or a Dual diet (0.5% vs 7.3%). Most GFP+ MVs were also positive for EpCAM and CD133 (98.3% and 92.9% respectively), suggesting their hepatic origin. In 71 biopsy-proven NAFLD patients, EpCAM+ CD133+ EVs were significantly higher in those with steatohepatitis compare to those with simple steatosis (286.4 ± 61.9 vs 758.4 ± 82.3; p < 0.001). Patients with ballooning 367 ± 40.6 vs 532.0 ± 45.1; p = 0.01 and lobular inflammation (321.1 ± 74.1 vs 721.4 ± 80.1; p = 0.001), showed higher levels of these EVs. These findings were replicated in an independent cohort.
Conclusions
Circulating levels of EpCAM+ CD133+ MVs in clinical and experimental NAFLD were increased in the presence of steatohepatitis, showing high potential as a non-invasive biomarker for the evaluation and management of these patients. | es |
dc.format | application/pdf | es |
dc.format.extent | 11 p. | es |
dc.language.iso | eng | es |
dc.publisher | Wiley | es |
dc.relation.ispartof | Liver International, 43 (9), 1909-1919. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | CD133 | es |
dc.subject | EpCAM | es |
dc.subject | NAFLD | es |
dc.subject | Extracellular vesicles | es |
dc.title | Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://onlinelibrary.wiley.com/doi/10.1111/liv.15604 | es |
dc.identifier.doi | 10.1111/liv.15604 | es |
dc.journaltitle | Liver International | es |
dc.publication.volumen | 43 | es |
dc.publication.issue | 9 | es |
dc.publication.initialPage | 1909 | es |
dc.publication.endPage | 1919 | es |
dc.contributor.funder | Consejeria de Economia, Conocimiento, Empresas y Universidad, Junta de Andalucia | es |
dc.contributor.funder | Consejeria de salud y Familia | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |
dc.contributor.funder | Junta de Andalucia | es |
dc.contributor.funder | Sociedad Andaluza de patologia Digestiva | es |